Supply Chain Planning
Software for Life Sciences

Patient access depends on the reliable availability of medicines, biologics and medical devices. Planning coordinates demand, materials, capacity, inventory and distribution while managing shelf life, cold-chain requirements, long lead times and strict regulatory obligations — constraints that, mishandled, translate directly into shortages or waste.

Typical gains include higher product availability and service levels, better capacity and equipment utilization, and faster response to disruption. These come alongside lower inventory, reduced expiry and waste, and stronger cost control across regulated manufacturing and distribution networks.

Because demand, supply, inventory, production, procurement and distribution sit in one environment, a planner can see how a single decision ripples into capacity, materials, service, cost and compliance elsewhere — turning isolated trade-offs into coordinated choices rather than downstream surprises.

It weighs remaining shelf life, demand, lead times, storage conditions and stock location when deciding where product should be held or used, prioritizing stock on FEFO principles. The effect is fewer write-offs and less excess without starving any market of supply.

It is the coordination of demand, supply, inventory, production, procurement and distribution across pharmaceutical, biotech and medical device operations — accounting for shelf life, cold-chain conditions, quality controls, limited capacity, supplier dependencies and patient-service obligations.

Beyond core materials, inventory, capacity, sourcing and distribution planning, look for how well it handles the industry's edge cases: expiry and batch production, long lead times, new-product launches, external manufacturers and market-specific regulatory requirements — while keeping plans executable.

Shelf life stops being a checkbox and starts steering decisions when it dictates how much to produce, where to position it, and which demand it can serve. Short-dated biologics, for example, force production and distribution timing to be planned backward from expiry rather than forward from capacity.

Temperature-controlled capacity is finite and expensive, transit adds risk, and usable life erodes with every handling step. Planning has to reconcile that limited cold capacity with regional demand and shelf life simultaneously, rather than treating storage as unconstrained.

AI accelerates the analysis of changing demand, supply risk, capacity limits and operational dependencies. Paired with advanced optimization, governed workflows and embedded industry logic, it supports scenario comparison, faster replanning and coordinated execution — while keeping people in the loop where judgment and accountability matter.

It lets teams test alternative demand, sourcing, inventory, capacity and production decisions before acting — showing how a supplier disruption, plant downtime, launch uncertainty or demand surge would hit service, cost, compliance, inventory and feasibility.

Planning produces a recommendation; execution turns it into coordinated operational action. In life sciences that means the decision has to reflect materials, capacity, business rules, quality and regulatory requirements and current conditions, so it stays feasible when it moves from analysis into production and supply.

It reassesses demand, sourcing, inventory, capacity and production as conditions change, compares feasible responses and moves selected actions into coordinated execution — with customer-defined policies, traceability and human oversight letting teams increase autonomy without losing control.

It uses existing master data, inventory, orders, capacity, production and procurement information as planning inputs, working alongside operational systems and returning coordinated plans or decisions for execution through established business processes — so it augments the system of record rather than replacing it.